David Nierengarten wrote this MF piece today. A lot of the article pertains to a new antibiotic for "super bugs". I'm assuming this is the same market our Nabi is going after. hmmmmm not sure what to make of this except to say they treat the infection after it occurs rather than Nabi's StaphVax vaccine which aims to prevent the infection in the first place. Nabi claims they are a low cost solution compared to current treatment options. I wonder how this drug will be priced.They are also in Phase II trials for blood infections but are in Phase III trials for other indications. They may get to market before Nabi, at least in the US?Any ideas or opinions , this board seems very quiet.CheersTimhttp://www.fool.com/News/mft/2004/mft04011305.htm?source=mpmftlistVicuron's Booster Shot By David Nierengarten January 13, 2004 Vicuron Pharmaceuticals' (Nasdaq: MICU) stock value has grown 20% in the past five days of trading, thanks to positive news surrounding its new "super-tough" antibiotic, dalbavancin. In Phase II trials, Vicuron's dalbavancin outperformed competitor vancomycin with response rates of 87% to 50%. Vancomycin is the "antibiotic of last resort" in hospitals used treat tough bacterial infections resistant to penicillin-derived versions. However, even mighty vancomycin has been defeated by crafty superbugs bred by the overuse of antibiotics.Vicuron's eyeing to grab a piece of the pie from vancomycin, which has annual sales in the $300 million range. Stiffening its competitive stance, dalbavancin is injected only once weekly, while vancomycin is injected twice daily. In addition to this trial, which was centered on acquired bloodstream infections, Vicuron has dalbavancin in two Phase III trials for skin and soft tissue infections. In this application, the drug maker's competitor is Cubist Pharmaceuticals (Nasdaq: CBST), which has an already approved drug called Cubicin. However, Cubicin must be injected once daily compared to dalbavancin's once-weekly dosing.Vicuron is not a one-trick pony, though. The company has filed a New Drug Application for their lead antifungal drug, anidulafungin. Vicuron faces some stiff competition in this market, with big pharma players like Pfizer's (NYSE: PFE) Diflucan (recently off-patent) and Vfend, along with Merck's (NYSE: MRK) Cancidas crowding the space.These drugs are poised to generate about $1.5 billion in revenue, with more than $600 million coming from the newer Vfend and Cancidas. Fungal infections are a growing market, due to increasing numbers of immuno-compromised patients, and the market can most likely support another effective anti-fungal. At the same time, revenues will likely be closer to the $500 million mark at their peak, rather than the $1 billion mark that defines a blockbuster drug.With the recent run-up, however, Vicuron is sporting an enterprise value north of $1 billion. Given the size of the markets and the many competing drugs, it is getting harder to justify those lofty heights.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, A